Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

Springerplus. 2016 Jan 22:5:65. doi: 10.1186/s40064-016-1713-8. eCollection 2016.

Abstract

To treat current infectious diseases, different therapies are used that include drugs or vaccines or both. Currently, the world is facing an increasing problem of drug resistance from many pathogenic microorganisms. In majority of cases, when vaccines are used, formulations consist of live attenuated microorganisms. This poses an additional risk of infection in immunocompromised patients and people suffering from malnutrition in developing countries. Therefore, there is need to improve drug therapy as well as to develop next generation vaccines, in particular against infectious diseases with highest mortality rates. For patients in developing countries, costs related to treatments are one of the major hurdles to reduce the disease burden. In many cases, use of prophylactic vaccines can help to control the incidence of infectious diseases. In the present review, we describe some infectious diseases with high impact on health of people in low and middle income countries. We discuss the prospects of plants as alternative platform for the development of next-generation subunit vaccines that can be a cost-effective source for mass immunization of people in developing countries.

Keywords: Adjuvants; Biopharmaceuticals; Drug resistant microorganisms; Infectious diseases; Next generation vaccines; Plant-based vaccines.

Publication types

  • Review